ONCOCYTE CORP.

ONCOCYTE CORP.

Share · US68235C2061 · OCX · A3EQV9 (XFRA)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ONCOCYTE CORP.
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
7
4
0
0
No Price
28.04.2026 20:16
Current Prices from ONCOCYTE CORP.
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
IMDX
USD
28.04.2026 20:16
4,12 USD
0,28 USD
+7,29 %
IEXG: IEX
IEX
IMDX
USD
28.04.2026 19:59
4,19 USD
0,34 USD
+8,98 %
XLON: London
London
0KCC.L
USD
28.04.2026 18:03
4,24 USD
0,40 USD
+10,29 %
Share Float & Liquidity
Free Float 27,15 %
Shares Float 7,29 M
Shares Outstanding 26,84 M
Company Profile for ONCOCYTE CORP. Share
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Company Data

Name ONCOCYTE CORP.
Company OncoCyte Corporation
Symbol OCX
Website https://oncocyte.com
Primary Exchange XFRA Frankfurt
WKN A3EQV9
ISIN US68235C2061
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Joshua Riggs
Market Capitalization 92 Mio
Country United States of America
Currency EUR
Employees 0,0 T
Address 15 Cushing, 92618 Irvine
IPO Date 2015-12-30
Dividends from 'ONCOCYTE CORP.'
Ex-Date Dividend per Share
15.03.2022 0,01 USD

Stock Splits

Date Split
25.07.2023 1:20

ID Changes

Date From To
18.06.2025 OCX IMDX

Ticker Symbols

Name Symbol
Frankfurt 7OC0.F
London 0KCC.L
NASDAQ IMDX
NASDAQ OCX
More Shares
Investors who hold ONCOCYTE CORP. also have the following shares in their portfolio:
Leverage Shares 2X Long MP Daily ETF
Leverage Shares 2X Long MP Daily ETF ETF
SINGHAIYI GROUP
SINGHAIYI GROUP Share